AzTrials
AzTrials

Multiple TraumaNCT01669577

Independent Predictors of Mortality in Polytrauma Patients

An observational study of Multiple Trauma, run by University of Sao Paulo at 1 site in Brazil.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Prospective observational trial searching for independent predictors of mortality. Data was collected at trauma scene, ER, three and 24 hours of hospital stay.The patients will be followed for 30 days after hospital admission. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Multiple Trauma
What is being tested?
analysis of blood samples and clinical features
Type of treatment
Surgery or procedure
How many people
200 participants
Where
1 siteBrazil
Study dates
Oct 2010to Aug 2014
Phase
Observational
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Severe trauma patients evaluated at trauma scene

Who may be able to join

  • severe trauma (ISS - Injury Severity Score- >15)

Who cannot join

  • under 18 years old patient,
  • technical problems during rescue maneuvers,
  • impossibility of blood sample draw during rescue
  • informed consent not provided

Trial locations and contacts

1 site in 1 country.

Brazil1 site
  • Instituto Central do Hospital das Clínicas da Universidade de São Paulo

    São Paulo, São Paulo, 05403000

Other trials in Brazil

About this study

Official title: Independent Predictors of Mortality in Polytrauma Patients: a Prospective, Observational, Longitudinal Study

Prospective observational trial searching for independent predictors of mortality. Data was collected at trauma scene, ER, three and 24 hours of hospital stay.The patients will be followed for 30 days after hospital admission.

Read the detailed description

The study protocol was approved by the Institutional Medical Ethics Committee (CAPPesq 1081/09) and received financial support from the São Paulo State Research Foundation (Fundação de Amparo à Pesquisa do Estado de São Paulo - FAPESP) under no. 2010/03315-4.

At the end of data prospecting, 334 patients with severe trauma (Injury Severity Score, ISS, >15), assisted by the rescue system and taken to HCFMUSP-Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo- (by land and helicopter) were included in the study. This screening strategy included trauma patients with severe confirmed bleeding, patients with severe traumatic brain injury (TBI) and patients facing high-energy trauma (a marked characteristic of this trauma center). Patients under 18 years of age were excluded ( Figure 1).

In total, 78 patients were excluded because they did not fit the above criteria, leaving 256 patients for analysis. Of this total, 34 patients died before arriving at the emergency room, and 22 were removed from the analysis due to incomplete data, not signing the informed consent form or due to any situation in which the data collection could compromise victim care(care Figure(Figure 1).

All patients had data recorded at the following times: 1, at the trauma scene; 2, in the emergency room; 3, at 3 hours after hospital admission; and 4, at 24 hours after hospitalization.

Data regarding gender, age, trauma and trauma mechanism, medical procedures performed at all stages, time until arrival at the hospital and comorbidities were recorded. The clinical data collected were as follows: systolic blood pressure (SBP); diastolic blood pressure (DBP); heart rate (HR); respiratory rate (RR); arterial hemoglobin oxygen saturation (SAT); Glasgow Coma Scale (GCS) score; and pupil pattern. The following laboratory data were collected through peripheral venipuncture at the hospital stages: pH(hydrogenic potential); base excess (BE); bicarbonate (BIC); partial oxygen pressure (pO2); partial carbon dioxide pressure (pCO2); arterial hemoglobin oxygen saturation; lactate; sodium (Na+); potassium (K+); ionized calcium (Ca2+); glucose; hemoglobin (Hb); hematocrit (Ht); serum creatine phosphokinase (CPK); platelets and leukocytes. Data regarding volume expansion [crystalloids (CRYSTAL), colloids (COLO)], diuresis and water balance were also collected. The use of blood products [packed red blood cells (PRBC), fresh frozen plasma (FFP), platelet concentrates (PLAT), cryoprecipitate concentrates (concentrates (CRYO)] was computed, and the use of vasoactive drugs (VAD) was scored at the respective times. Patient follow-up was conducted at the intensive care unit (ICU), and time of ICU stay (days in the ICU), days under mechanic ventilation (days under MV), the presence or absence of sepsis, coagulopathy and acute renal failure (ARF) were recorded.

Blood coagulation data were collected as follows: time point 1, International Normalized Ratio (INR) and prothrombin time (PT); and time points 2, 3 and 4, INR, PT, activated partial thromboplastin time (aPTT), the respective ratio between aPTT of patients and controls (R) and thrombin time (TT).

The following severity indexes were calculated: ISS, revised trauma score (RTS); trauma and injury severity score (TRISS); and simplified acute physiology score (SAPS) 3 (the latter when the patient was in the ICU).

At time point 1, blood tests were performed using the i-STAT® device (Abbott, USA; PT/INR and CG4+ and CG8+ kits). At the hospital stages, the analyses used the clinical analysis methodology of the HCFMUSP.

Clinical follow-up was conducted for 30 days after initial trauma.

Statistical analyses The sample power analysis was conducted with a significance level of 0.05, power of 0.80, moderate correlation of 0.5 between time periods and assumption that the variability is equal within each factor (non-sphericity). Due to the effect size between 0.1 and 0.5, there was no need for samples larger than 140 patients. A total of 200 patients waswere defined conservatively, with a margin for possible deaths. The software G*Power 3.1.7 was used for sample size calculation.

The data analysis was divided into three interconnected parts. The first part refers to the descriptive data analysis and tests of association with death. The second part addressed the profiles of the time-dependent measures and their relationship with death through analysis of nonparametric variance for repeated measures. The third part includes the set of all previous analyses that resulted in a Generalized Estimating Equation (GEE).

For the first part, the analyses were performed with the overall sample (n=200) subdivided into two groups: deaths (n=52) and non-deaths (n=148). For qualitative variables, the two-tailed Fisher's exact test was used, and for quantitative variables, the two-tailed t test or the two-tailed Mann-Whitney test was used according to the normality of the variable, which was verified by the Anderson-Darling test.

In the second part, the profiles of each measure over time were analyzed for groups of survivors and non-survivors. Nonparametric analyses of variance (NPar ANOVA) were conducted.

Finally, in the third part, a GEE model was developed considering the family of binomial distributions (dichotomous response variable) with logit link function. Only the main effects of each measure were considered. The NPar ANOVA (p>0.1) was the test used for inclusion in the model. The variables for the final models were selected using the backward method, with output alpha equal to 0.05. All part 3 results were interpreted by estimating odds ratios (OR), their corresponding 95% confidence intervals and significance tests (p-value).

The significance level was set at 0.05, and the free software R 3.0.2 was used for performing the statistical analyses.

Conditions
Multiple Trauma
Being tested
analysis of blood samples and clinical features
Keywords
predictors, trauma, mortality
Medical subject headings
Multiple Trauma, Wounds and Injuries

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • analysis of blood samples and clinical featuresProcedure or surgery

    clinical follow up and biochemical analysis blood at 4 time points:1-prehospital; 2-emergency room; 3- surgical center; 4-intensive care unit . 30 days follow up

Study groups in NCT01669577
Study groupRoleWhat they receive
severe trauma patientsanalysis of blood samples and clinical features
Receives: Procedure: analysis of blood samples and clinical features

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Death

    30 days after trauma mortality evaluation

    Measured: Within the first 30 days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted21 Aug 2012 (estimated)
  2. Study startOct 2010
  3. Primary completionJun 2013
  4. Study completionAug 2014

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
200 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01669577
Sponsor's protocol ID
1081/09
Status last verified
Jan 2015
First submitted
8 Aug 2012
Last updated
9 Jan 2015
Data monitoring committee
Yes

Publications

  • da Costa LGV, Carmona MJC, Malbouisson LM, Rizoli S, Rocha-Filho JA, Cardoso RG, Auler-Junior JOC. Independent early predictors of mortality in polytrauma patients: a prospective, observational, longitudinal study. Clinics (Sao Paulo). 2017 Aug;72(8):461-468. doi: 10.6061/clinics/2017(08)02.

    PubMed 28954004

Questions about this trial

What is this clinical trial studying?

An observational study of Multiple Trauma, run by University of Sao Paulo at 1 site in Brazil.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 9 Jan 2015. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Brazil. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 9 Jan 2015). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Death (time frame: Within the first 30 days). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01669577, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Jan 2015.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in